Hengrui Pharmaceutical (01276): Phorolapitampalonosetron for injection was approved for drug registration

Zhitongcaijing · 2d ago

Zhitong Finance App News, Hengrui Pharmaceutical (01276) issued an announcement. Recently, Fujian Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, received a notice from the State Drug Administration to approve the addition of a Class 1 innovative drug independently developed by the company and China's first ultra-long-lasting original dual-target antiemetic injection with phosphorolapitamparonosetron for injection.

Injectable phosphorapitamparonosetron was approved for marketing in May 2025 to prevent acute and delayed nausea and vomiting caused by highly emetic chemotherapy (HEC) in adult patients.

Phorolapitamparonosetron for injection is a compound preparation that can simultaneously antagonize both NK-1 receptors and 5-HT3 receptors to inhibit vomiting reflexes, and has differentiated advantages such as high solubility, good safety, and long-term effects. With the advantage of an ultra-long half-life of nearly 8 days, the product only needs to be administered once per chemotherapy cycle, and can simultaneously cover the acute phase, delay period, and ultra-delay period of CINV. According to inquiries, similar NK-1 receptor/5-HT3 receptor antagonist compounds that have been marketed abroad are Helsinn Healthcare's AKynzeo intravenous preparation (forneitupitan/palonosetron) and oral capsule formulation (netupitan/palonosetron). Both products have been marketed domestically. Up to now, the total R&D investment in projects related to injectable phosphorapitamparonosetron is approximately RMB 259.5 million (unaudited).